Europe Must Seize Opportunity For Change
Five Key Issues For EU Pharma Strategy Cited By Medicines For Europe
The EU’s upcoming pharma strategy offers an important opportunity for change, according to Medicines for Europe. The off-patent industry body has set out five key issues that should be priorities for the EU Commission.
You may also be interested in...
Medicines for Europe has highlighted the need for an improved digital strategy across the EU in order to improve patient information and access to medicines, among other benefits like reducing the risk of supply disruptions, especially in the context of the current pandemic.
Partners Apotex and Ambio have announced approval of a second US teriparatide generic from the FDA, adding another Forteo rival to the market and removing hopes that Teva’s recently approved first generic could benefit from 180 days of market exclusivity. Further competition is also in the works with Amphastar awaiting FDA action on a further teriparatide ANDA.
Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.